{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:09:09Z","timestamp":1772921349405,"version":"3.50.1"},"reference-count":154,"publisher":"Bentham Science Publishers Ltd.","issue":"15","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,10,16]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Inhibitors of cholinesterases are a wide group of low molecular weight compounds with a\nsignificant role in the current pharmacology. Besides the pharmacological importance, they are also\nknown as toxic compounds like military nerve agents. In the pharmacology, drugs for Alzheimer disease,\nmyasthenia gravis and prophylaxis of poisoning by nerve agents can be mentioned as the relevant\napplications. Besides this, anti-inflammation and antiphrastic drugs are other pharmacological applications\nof these inhibitors. This review is focused on a survey of cholinesterase inhibitors with known or\nexpected pharmacological impact and indications of their use. Recent literature with comments is provided\nhere as well.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557519666191018170908","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T06:39:55Z","timestamp":1572244795000},"page":"1532-1542","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Inhibitors of Cholinesterases in Pharmacology: the Current Trends"],"prefix":"10.2174","volume":"20","author":[{"given":"Miroslav","family":"Pohanka","sequence":"first","affiliation":[{"name":"Faculty of Military Health Sciences, University of Defense, Trebesska 1575, Hradec Kralove, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1","volume":"8","author":"Masson P.","year":"1998","unstructured":"Masson P.; Froment M.T.; Fortier P.L.; Visicchio J.E.; Bartels C.F.; Lockridge O.; Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim Biophys Acta 1998,8,1-2","journal-title":"Biochim Biophys Acta"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/JCP.0000000000000347","volume":"35","author":"Shram M.J.","year":"2015","unstructured":"Shram M.J.; Cohen-Barak O.; Chakraborty B.; Bassan M.; Schoedel K.A.; Hallak H.; Eyal E.; Weiss S.; Gilgun-Serki Y.; Sellers E.M.; Faulknor J.; Spiegelstein O.; Assessment of pharmacokinetic and pharmacodynamic interactions between albumin-fused mutated butyrylcholinesterase and intravenously administered cocaine in recreational cocaine users. J Clin Psychopharmacol 2015,35(4),396-405","journal-title":"J Clin Psychopharmacol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1021\/jm061471k","volume":"50","author":"Hyatt J.L.","year":"2007","unstructured":"Hyatt J.L.; Moak T.; Hatfield M.J.; Tsurkan L.; Edwards C.C.; Wierdl M.; Danks M.K.; Wadkins R.M.; Potter P.M.; Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem 2007,50(8),1876-1885","journal-title":"J Med Chem"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4149\/BLL_2013_153","volume":"114","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Butyrylcholinesterase as a biochemical marker, a review. Brat Med J 2013,114(12),726-734","journal-title":"Brat Med J"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5507\/bp.2011.036","volume":"155","author":"Pohanka M.","year":"2011","unstructured":"Pohanka M.; Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Olomouc 2011,155(3),219-229","journal-title":"Biomed Pap Olomouc"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bbr.2010.11.033","volume":"221","author":"Klinkerberg I.","year":"2011","unstructured":"Klinkerberg I.; Sambeth A.; Blokland A.; Acetylcholine and attention. Behav Brain Res 2011,221(2),430-442","journal-title":"Behav Brain Res"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cbi.2016.04.014","volume":"259","author":"Campoy F.J.","year":"2016","unstructured":"Campoy F.J.; Vidal C.J.; Munoz-Delgado E.; Montenegro M.F.; Cabezas-Herrera J.; Nieto-Ceron S.; Cholinergic system and cell proliferation. Chem Biol Interact 2016,259(Pt B),257-265","journal-title":"Chem Biol Interact"},{"key":"ref=8","first-page":"773","volume":"66","author":"Lewartowski B.","year":"2015","unstructured":"Lewartowski B.; Mackiewicz U.; The non-neuronal heart\u2019s acetylcholine in health and disease. J Physiol Pharmacol 2015,66(6),773-778","journal-title":"J Physiol Pharmacol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3390\/ijms13022219","volume":"13","author":"Pohanka M.","year":"2012","unstructured":"Pohanka M.; Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci 2012,13(2),2219-2238","journal-title":"Int J Mol Sci"},{"key":"ref=10","first-page":"30186","volume":"24","author":"Tessier C.J.G.","year":"2017","unstructured":"Tessier C.J.G.; Emlaw J.R.; Cao Z.Q.; Javier Perez-Areales F.; Salameh J.J.; Prinston J.E.; McNulty M.S.; daCosta C.J.B.; Back to the future: Rational maps for exploring acetylcholine receptor space and time. Biochim Biophys Acta 2017,24(17),30186-30183","journal-title":"Biochim Biophys Acta"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"40207","DOI":"10.1074\/jbc.R112.407668","volume":"287","author":"Changeux J.P.","year":"2012","unstructured":"Changeux J.P.; The nicotinic acetylcholine receptor: The founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem 2012,287(48),40207-40215","journal-title":"J Biol Chem"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1871524916666160302103033","volume":"16","author":"De Angelis F.","year":"2016","unstructured":"De Angelis F.; Tata A.M.; Analgesic effects mediated by muscarinic receptors: Mechanisms and pharmacological approaches. Cent Nerv Syst Agents Med Chem 2016,16(3),218-226","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/toxins9090268","volume":"9","author":"Sundeen G.","year":"2017","unstructured":"Sundeen G.; Barbieri J.T.; Vaccines against botulism. Toxins 2017,9(9),268","journal-title":"Toxins"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0975-5950.196133","volume":"7","author":"Dutta S.R.","year":"2016","unstructured":"Dutta S.R.; Passi D.; Singh M.; Singh P.; Sharma S.; Sharma A.; Botulinum toxin the poison that heals: A brief review. Natl J Maxillofac Surg 2016,7(1),10-16","journal-title":"Natl J Maxillofac Surg"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/mds.25582","volume":"28","author":"Ramirez-Castaneda J.","year":"2013","unstructured":"Ramirez-Castaneda J.; Jankovic J.; Comella C.; Dashtipour K.; Fernandez H.H.; Mari Z.; Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013,28(13),1775-1783","journal-title":"Mov Disord"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tox.2013.02.006","volume":"306","author":"Wheeler A.","year":"2013","unstructured":"Wheeler A.; Smith H.S.; Botulinum toxins: Mechanisms of action, antinociception and clinical applications. Toxicology 2013,306,124-146","journal-title":"Toxicology"},{"key":"ref=17","first-page":"780","volume":"69","author":"Petroianu G.A.","year":"2014","unstructured":"Petroianu G.A.; Pharmacists adolf schall and ernst ratzlaff and the synthesis of tabun-like compounds: A brief history. Pharmazie 2014,69(10),780-784","journal-title":"Pharmazie"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2710.2008.00972.x","volume":"34","author":"Lopez-Munoz F.","year":"2009","unstructured":"Lopez-Munoz F.; Garcia-Garcia P.; Alamo C.; The pharmaceutical industry and the german national socialist regime: Ig farben and pharmacological research. J Clin Pharm Ther 2009,34(1),67-77","journal-title":"J Clin Pharm Ther"},{"key":"ref=19","first-page":"27","volume":"14","author":"Mashkovsky M.D.","year":"1951","unstructured":"Mashkovsky M.D.; Kruglikova-Lvova R.P.; On the pharmacology of the new alkaloid galantamine. Farmakologiea Toxicologia (Moscow) 1951,14,27-30","journal-title":"Farmakologiea Toxicologia (Moscow)"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00023210-199707020-00001","volume":"7","author":"Rainer M.","year":"1997","unstructured":"Rainer M.; Galanthamine in alzheimer\u2019s disease - a new alternative to tacrine? CNS Drugs 1997,7(2),89-97","journal-title":"CNS Drugs"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/106002809402800612","volume":"28","author":"Crismon M.L.","year":"1994","unstructured":"Crismon M.L.; Tacrine: First drug approved for alzheimer\u2019s disease. Ann Pharmacother 1994,28(6),744-751","journal-title":"Ann Pharmacother"},{"key":"ref=22","first-page":"15","volume":"10","author":"Bell C.","year":"1964","unstructured":"Bell C.; Gershon S.; Experimental anticholinergic psychoto-mimetics - antagonism of yohimbine + tacrine (tha). Med Experiment 1964,10(1),15","journal-title":"Med Experiment"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/icb.1963.15","volume":"41","author":"Delalande I.S.","year":"1963","unstructured":"Delalande I.S.; Porter R.B.; Actions of tacrine and amiphenazole on acetylcholine metabolims in guinea pig ileum. Aust J Exp Biol Med Sci 1963,41(2),149","journal-title":"Aust J Exp Biol Med Sci"},{"key":"ref=24","first-page":"30050","volume":"31","author":"Pope C.N.","year":"2018","unstructured":"Pope C.N.; Brimijoin S.; Cholinesterases and the fine line between poison and remedy. Biochem Pharmacol 2018,31(18),30050-30059","journal-title":"Biochem Pharmacol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40266-017-0510-6","volume":"35","author":"Triantafylidis L.K.","year":"2018","unstructured":"Triantafylidis L.K.; Clemons J.S.; Peron E.P.; Roefaro J.; Zimmerman K.M.; Brain over bladder: A systematic review of dual cholinesterase inhibitor and urinary anticholinergic use. Drugs Aging 2018,35(1),27-41","journal-title":"Drugs Aging"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/molecules23010035","volume":"23","author":"Bourne Y.","year":"2017","unstructured":"Bourne Y.; Marchot P.; Hot spots for protein partnerships at the surface of cholinesterases and related alpha\/beta hydrolase fold proteins or domains-a structural perspective. Molecules 2017,23(1),35","journal-title":"Molecules"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jep.2017.12.015","volume":"215","author":"Sahoo A.K.","year":"2018","unstructured":"Sahoo A.K.; Dandapat J.; Dash U.C.; Kanhar S.; Features and outcomes of drugs for combination therapy as multi-targets strategy to combat alzheimer\u2019s disease. J Ethnopharmacol 2018,215,42-73","journal-title":"J Ethnopharmacol"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jagp.2017.09.027","volume":"26","author":"Renn B.N.","year":"2018","unstructured":"Renn B.N.; Asghar-Ali A.A.; Thielke S.; Catic A.; Martini S.R.; Mitchell B.G.; Kunik M.E.; A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. Am J Geriatr Psychiatry 2018,26(2),134-147","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40266-017-0499-x","volume":"34","author":"Khoury R.","year":"2017","unstructured":"Khoury R.; Patel K.; Gold J.; Hinds S.; Grossberg G.T.; Recent progress in the pharmacotherapy of alzheimer\u2019s disease. Drugs Aging 2017,34(11),811-820","journal-title":"Drugs Aging"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.4155\/fmc-2017-0094","volume":"9","author":"Panek D.","year":"2017","unstructured":"Panek D.; Wichur T.; Godyn J.; Pasieka A.; Malawska B.; Advances toward multifunctional cholinesterase and beta-amyloid aggregation inhibitors. Future Med Chem 2017,9(15),1835-1854","journal-title":"Future Med Chem"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/jgs.15020","volume":"65","author":"Mehta N.","year":"2017","unstructured":"Mehta N.; Rodrigues C.; Lamba M.; Wu W.; Bronskill S.E.; Herrmann N.; Gill S.S.; Chan A.W.; Mason R.; Day S.; Gurwitz J.H.; Rochon P.A.; Systematic review of sex-specific reporting of data: Cholinesterase inhibitor example. J Am Geriatr Soc 2017,65(10),2213-2219","journal-title":"J Am Geriatr Soc"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3390\/molecules22071192","volume":"22","author":"Ramsay R.R.","year":"2017","unstructured":"Ramsay R.R.; Tipton K.F.; Assessment of enzyme inhibition: A review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs. Molecules 2017,22(7),1192","journal-title":"Molecules"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14740338.2017.1351540","volume":"16","author":"Mohammad D.","year":"2017","unstructured":"Mohammad D.; Chan P.; Bradley J.; Lanctot K.; Herrmann N.; Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Expert Opin Drug Saf 2017,16(9),1009-1019","journal-title":"Expert Opin Drug Saf"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jnc.14026","volume":"2","author":"Masson P.","year":"2017","unstructured":"Masson P.; Nachon F.; Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning. J Neurochem 2017,2,26-40","journal-title":"J Neurochem"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4155\/fmc-2017-0036","volume":"9","author":"Knez D.","year":"2017","unstructured":"Knez D.; Sova M.; Kosak U.; Gobec S.; Dual inhibitors of cholinesterases and monoamine oxidases for alzheimer\u2019s disease. Future Med Chem 2017,9(8),811-832","journal-title":"Future Med Chem"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"17640","DOI":"10.1016\/S0021-9258(19)37091-7","volume":"267","author":"Shafferman A.","year":"1992","unstructured":"Shafferman A.; Kronman C.; Flashner Y.; Leitner M.; Grosfeld H.; Ordentlich A.; Gozes Y.; Cohen S.; Ariel N.; Barak D.; Harel M.; Silman I.; Sussman J.L.; Velan B.; Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem 1992,267(25),17640-17648","journal-title":"J Biol Chem"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-2797(99)00011-3","volume":"120","author":"Massoulie J.","year":"1999","unstructured":"Massoulie J.; Anselmet A.; Bon S.; Krejci E.; Legay C.; Morel N.; Simon S.; The polymorphism of acetylcholinesterase: Post-translational processing, quaternary associations and localization. Chem Biol Interact 1999,120,29-42","journal-title":"Chem Biol Interact"},{"key":"ref=38","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/938a4e59-a5d1-448c-b7c1-632bf9e7e8ef","volume":"6","author":"Pezzementi L.","year":"2011","unstructured":"Pezzementi L.; Nachon F.; Chatonnet A.; Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: An atypical butyrylcholinesterase from the medaka oryzias latipes. PLoS One 2011,6(2)","journal-title":"PLoS One"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbrc.2010.12.084","volume":"404","author":"Nawaz S.A.","year":"2011","unstructured":"Nawaz S.A.; Ayaz M.; Brandt W.; Wessjohann L.A.; Westermann B.; Cation-\u03c0 and \u03c0-\u03c0 stacking interactions allow selective inhibition of butyrylcholinesterase by modified quinine and cinchonidine alkaloids. Biochem Biophys Res Commun 2011,404(4),935-940","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/13543776.2012.701620","volume":"22","author":"Pohanka M.","year":"2012","unstructured":"Pohanka M.; Acetylcholinesterase inhibitors: A patent review (2008 - present). Expert Opin Ther Pat 2012,22(8),871-886","journal-title":"Expert Opin Ther Pat"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/138161206775193127","volume":"12","author":"Johnson G.","year":"2006","unstructured":"Johnson G.; Moore S.W.; The peripheral anionic site of acetylcholinesterase: Structure, functions and potential role in rational drug design. Curr Pharm Des 2006,12(2),217-225","journal-title":"Curr Pharm Des"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.1021\/bi971425+","volume":"36","author":"Saxena A.","year":"1997","unstructured":"Saxena A.; Redman A.M.; Jiang X.; Lockridge O.; Doctor B.P.; Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997,36(48),14642-14651","journal-title":"Biochemistry"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tox.2004.07.009","volume":"206","author":"Cometa M.F.","year":"2005","unstructured":"Cometa M.F.; Lorenzini P.; Fortuna S.; Volpe M.T.; Meneguz A.; Palmery M.; In vitro inhibitory effect of aflatoxin b-1 on acetylcholinesterase activity in mouse brain. Toxicology 2005,206(1),125-135","journal-title":"Toxicology"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.talanta.2015.07.068","volume":"144","author":"Stepurska K.V.","year":"2015","unstructured":"Stepurska K.V.; Soldatkin O.O.; Arkhypova V.M.; Soldatkin A.P.; Lagarde F.; Jaffrezic-Renault N.; Dzyadevych S.V.; Development of novel enzyme potentiometric biosensor based on ph-sensitive field-effect transistors for aflatoxin b1 analysis in real samples. Talanta 2015,144,1079-1084","journal-title":"Talanta"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/jm040787u","volume":"47","author":"Cavalli A.","year":"2004","unstructured":"Cavalli A.; Bottegoni G.; Raco C.; De Vivo M.; Recanatini M.; A computational study of the binding of propidium to the peripheral anionic site of human acetylcholinesterase. J Med Chem 2004,47(16),3991-3999","journal-title":"J Med Chem"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cbi.2006.05.013","volume":"162","author":"Mazzanti C.M.","year":"2006","unstructured":"Mazzanti C.M.; Spanevello R.M.; Obregon A.; Pereira L.B.; Streher C.A.; Ahmed M.; Mazzanti A.; Graca D.L.; Morsch V.M.; Schetinger M.R.; Ethidium bromide inhibits rat brain acetylcholinesterase activity in vitro. Chem Biol Interact 2006,162(2),121-127","journal-title":"Chem Biol Interact"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jps.2600640313","volume":"64","author":"Holtje H.D.","year":"1975","unstructured":"Holtje H.D.; Kjier L.B.; Nature of anionic or alpha-site of cholinesterase. J Pharm Sci 1975,64(3),418-420","journal-title":"J Pharm Sci"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.8122110","volume":"263","author":"Gilson M.K.","year":"1994","unstructured":"Gilson M.K.; Straatsma T.P.; McCammon J.A.; Ripoll D.R.; Faerman C.H.; Axelsen P.H.; Silman I.; Sussman J.L.; Open \u201cback door\u201d in a molecular dynamics simulation of acetylcholinesterase. Science 1994,263(5151),1276-1278","journal-title":"Science"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cca.2007.02.001","volume":"380","author":"Boopathy R.","year":"2007","unstructured":"Boopathy R.; Rajesh R.V.; Darvesh S.; Layer P.G.; Human serum cholinesterase from liver pathological samples exhibit highly elevated aryl acylamidase activity. Clin Chim Acta 2007,380,151-156","journal-title":"Clin Chim Acta"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1515\/BC.2008.041","volume":"389","author":"Montenegro M.F.","year":"2008","unstructured":"Montenegro M.F.; Maria T.M.; de la Cadena M.P.; Campoy F.J.; Munoz-Delgado E.; Vidal C.J.; Human butyrylcholinesterase components differ in aryl acylamidase activity. Biol Chem 2008,389(4),425-432","journal-title":"Biol Chem"},{"key":"ref=51","volume":"6","author":"Berg L.","year":"2011","unstructured":"Berg L.; Andersson C.D.; Artursson E.; Hornberg A.; Tunemalm A.K.; Linusson A.; Ekstrom F.; Targeting acetylcholinesterase: Identification of chemical leads by high throughput screening, structure determination and molecular modeling. PLoS One 2011,6(11)","journal-title":"PLoS One"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14656566.2013.760543","volume":"14","author":"Cheewakriengkrai L.","year":"2013","unstructured":"Cheewakriengkrai L.; Gauthier S.; A 10-year perspective on donepezil. Expert Opin Pharmacother 2013,14(3),331-338","journal-title":"Expert Opin Pharmacother"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.2174\/156802611798184409","volume":"11","author":"Rampa A.","year":"2011","unstructured":"Rampa A.; Belluti F.; Gobbi S.; Bisi A.; Hybrid-based multi-target ligands for the treatment of alzheimer\u2019s disease. Curr Top Med Chem 2011,11(22),2716-2730","journal-title":"Curr Top Med Chem"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/0929867003375281","volume":"7","author":"Bai D.L.","year":"2000","unstructured":"Bai D.L.; Tang X.C.; He X.C.; Huperzine a, a potential therapeutic agent for treatment of alzheimer\u2019s disease. Curr Med Chem 2000,7(3),355-374","journal-title":"Curr Med Chem"},{"key":"ref=55","first-page":"413","volume":"19","author":"Liu J.","year":"1998","unstructured":"Liu J.; Zhang H.Y.; Tang X.C.; Wang B.; He X.C.; Bai D.L.; Effects of synthetic (-)-huperzine a on cholinesterase activities and mouse water maze performance. Zhongguo Yao Li Xue Bao 1998,19(5),413-416","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.ejmech.2011.03.058","volume":"46","author":"Luo W.","year":"2011","unstructured":"Luo W.; Li Y.P.; He Y.; Huang S.L.; Li D.; Gu L.Q.; Huang Z.S.; Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-alzheimer agents. Eur J Med Chem 2011,46(6),2609-2616","journal-title":"Eur J Med Chem"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1211\/jpp.59.9.0003","volume":"59","author":"Jogani V.V.","year":"2007","unstructured":"Jogani V.V.; Shah P.J.; Mishra P.; Mishra A.K.; Misra A.R.; Nose-to-brain delivery of tacrine. J Pharm Pharmacol 2007,59(9),1199-1205","journal-title":"J Pharm Pharmacol"},{"key":"ref=58","first-page":"S22","volume":"8","author":"Knapp M.J.","year":"1994","unstructured":"Knapp M.J.; Gracon S.I.; Davis C.S.; Solomon P.R.; Pendlebury W.W.; Knopman D.S.; Efficacy and safety of high-dose tacrine - a 30 week evaluation Alzheimer Dis. Assoc Dis 1994,8,S22-S31","journal-title":"Assoc Dis"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199210293271801","volume":"327","author":"Davis K.L.","year":"1992","unstructured":"Davis K.L.; Thal L.J.; Gamzu E.R.; Davis C.S.; Woolson R.F.; Gracon S.I.; Drachman D.A.; Schneider L.S.; Whitehouse P.J.; Hoover T.M.; Morris J.C.; Kawas C.H.; Knopman D.S.; Earl N.L.; Kumar V.; Doody R.S.; A double-blind, placebo-controlled multicenter study of tacrine for alzheimers-disease. N Engl J Med 1992,327(18),1253-1259","journal-title":"N Engl J Med"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/00032719.2012.757703","volume":"46","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Spectrophotomeric assay of aflatoxin b1 using acetylcholinesterase immobilized on standard microplates. Anal Lett 2013,46(8),1306-1315","journal-title":"Anal Lett"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00604-010-0317-1","volume":"170","author":"Arduini F.","year":"2010","unstructured":"Arduini F.; Amine A.; Moscone D.; Palleschi G.; Biosensors based on cholinesterase inhibition for insecticides, nerve agents and aflatoxin b-1 detection (review). Microchim Acta 2010,170(3-4),193-214","journal-title":"Microchim Acta"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.3390\/ijms14059873","volume":"14","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Dobes P.; Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase. Int J Mol Sci 2013,14,9873-9882","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2174\/1389557514666140529223436","volume":"16","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; The effects of caffeine on the cholinergic system. Mini Rev Med Chem 2014,16(6),543-549","journal-title":"Mini Rev Med Chem"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4155\/fmc.11.67","volume":"3","author":"da Silva V.B.","year":"2011","unstructured":"da Silva V.B.; de Andrade P.; Kawano D.F.; Morais P.A.B.; de Almeida J.R.; Carvalho I.; Taft C.A.; da Silva C.; In silico design and search for acetylcholinesterase inhibitors in alzheimer\u2019s disease with a suitable pharmacokinetic profile and low toxicity. Future Med Chem 2011,3(8),947-960","journal-title":"Future Med Chem"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","volume":"8","author":"Lilienfeld S.","year":"2002","unstructured":"Lilienfeld S.; Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with alzheimer\u2019s disease. CNS Drug Rev 2002,8(2),159-176","journal-title":"CNS Drug Rev"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/156720510790274455","volume":"7","author":"Darreh-Shori T.","year":"2010","unstructured":"Darreh-Shori T.; Soininen H.; Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with alzheimer\u2019s disease: A review of recent clinical studies. Curr Alzheimer Res 2010,7(1),67-73","journal-title":"Curr Alzheimer Res"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0024-3205(90)90429-U","volume":"46","author":"Thomsen T.","year":"1990","unstructured":"Thomsen T.; Kewitz H.; Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990,46(21),1553-1558","journal-title":"Life Sci"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.toxlet.2009.07.025","volume":"190","author":"Jokanovic M.","year":"2009","unstructured":"Jokanovic M.; Medical treatment of acute poisoning with organophosphorus and carbamate pesticides. Toxicol Lett 2009,190(2),107-115","journal-title":"Toxicol Lett"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"Colovic M.B.","year":"2013","unstructured":"Colovic M.B.; Krstic D.Z.; Lazarevic-Pasti T.D.; Bondzic A.M.; Vasic V.M.; Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr Neuropharmacol 2013,11(3),315-335","journal-title":"Curr Neuropharmacol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/jm8002075","volume":"51","author":"Darvesh S.","year":"2008","unstructured":"Darvesh S.; Darvesh K.V.; McDonald R.S.; Mataija D.; Walsh R.; Mothana S.; Lockridge O.; Martin E.; Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem 2008,51(14),4200-4212","journal-title":"J Med Chem"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10565-013-9259-9","volume":"29","author":"Marrs T.C.","year":"2013","unstructured":"Marrs T.C.; Maynard R.L.; Neurotranmission systems as targets for toxicants: A review. Cell Biol Toxicol 2013,29(6),381-396","journal-title":"Cell Biol Toxicol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jat.3048","volume":"35","author":"Kalasz H.","year":"2015","unstructured":"Kalasz H.; Nurulain S.M.; Veress G.; Antus S.; Darvas F.; Adeghate E.; Adem A.; Hashemi F.; Tekes K.; Mini review on blood-brain barrier penetration of pyridinium aldoximes. J Appl Toxicol 2015,35(2),116-123","journal-title":"J Appl Toxicol"},{"key":"ref=73","first-page":"1471","volume":"10","author":"Costantino H.R.","year":"2008","unstructured":"Costantino H.R.; Leonard A.K.; Brandt G.; Johnson P.H.; Quay S.C.; Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci 2008,10(9),1471-2202","journal-title":"BMC Neurosci"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pharmthera.2013.04.009","volume":"139","author":"Worek F.","year":"2013","unstructured":"Worek F.; Thiermann H.; The value of novel oximes for treatment of poisoning by organophosphorus compounds. Pharmacol Ther 2013,139(2),249-259","journal-title":"Pharmacol Ther"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/FPC.0b013e3282f1f12b","volume":"17","author":"Alfirevic A.","year":"2007","unstructured":"Alfirevic A.; Mills T.; Carr D.; Barratt B.J.; Jawaid A.; Sherwood J.; Smith J.C.; Tugwood J.; Hartkoorn R.; Owen A.; Park K.B.; Pirmohamed M.; Tacrine-induced liver damage: An analysis of 19 candidate genes. Pharmacogenet Genomics 2007,17(12),1091-1100","journal-title":"Pharmacogenet Genomics"},{"key":"ref=76","first-page":"13439","volume":"4","author":"Lane C.A.","year":"2017","unstructured":"Lane C.A.; Hardy J.; Schott J.M.; Alzheimer\u2019s disease. Eur J Neurol 2017,4(10),13439","journal-title":"Eur J Neurol"},{"key":"ref=77","first-page":"30216","volume":"15","author":"Crane P.K.","year":"2017","unstructured":"Crane P.K.; Trittschuh E.; Mukherjee S.; Saykin A.J.; Sanders R.E.; Larson E.B.; McCurry S.M.; McCormick W.; Bowen J.D.; Grabowski T.; Moore M.; Bauman J.; Gross A.L.; Keene C.D.; Bird T.D.; Gibbons L.E.; Mez J.; Incidence of cognitively defined late-onset alzheimer\u2019s dementia subgroups from a prospective cohort study. Alzheimers Dement 2017,15(17),30216-30219","journal-title":"Alzheimers Dement"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archneur.59.11.1737","volume":"59","author":"Kukull W.A.","year":"2002","unstructured":"Kukull W.A.; Higdon R.; Bowen J.D.; McCormick W.C.; Teri L.; Schellenberg G.D.; van Belle G.; Jolley L.; Larson E.B.; Dementia and alzheimer disease incidence: A prospective cohort study. Arch Neurol 2002,59(11),1737-1746","journal-title":"Arch Neurol"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0447.2011.01754.x","volume":"124","author":"Lobo A.","year":"2011","unstructured":"Lobo A.; Lopez-Anton R.; Santabarbara J.; de-la-Camara C.; Ventura T.; Quintanilla M.A.; Roy J.F.; Campayo A.J.; Lobo E.; Palomo T.; Rodriquez-Jimenez R.; Saz P.; Marcos G.; Incidence and lifetime risk of dementia and alzheimer\u2019s disease in a southern european population. Acta Psychiatr Scand 2011,124(5),372-383","journal-title":"Acta Psychiatr Scand"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1533317512442371","volume":"27","author":"Dimitrov I.","year":"2012","unstructured":"Dimitrov I.; Tzourio C.; Milanov I.; Deleva N.; Traykov L.; Prevalence of dementia and mild cognitive impairment in a bulgarian urban population. Am J Alzheimers Dis Other Demen 2012,27(2),131-135","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2012.07.001","volume":"136","author":"Himmelstein D.S.","year":"2012","unstructured":"Himmelstein D.S.; Ward S.M.; Lancia J.K.; Patterson K.R.; Binder L.I.; Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 2012,136(1),8-22","journal-title":"Pharmacol Ther"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2174\/09298673113206660258","volume":"21","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; Alzheimer\u2019s disease and oxidative stress. A review. Curr Med Chem 2014,21(3),356-364","journal-title":"Curr Med Chem"},{"key":"ref=83","first-page":"028","volume":"5","author":"Hamlett E.D.","year":"2017","unstructured":"Hamlett E.D.; Ledreux A.; Potter H.; Chial H.J.; Patterson D.; Espinosa J.M.; Bettcher B.M.; Granholm A.C.; Exosomal biomarkers in down syndrome and alzheimer's disease. Free Radic Biol Med 2017,5(17),028","journal-title":"Free Radic Biol Med"},{"key":"ref=84","volume":"17","author":"He J.","year":"2017","unstructured":"He J.; Liao T.; Zhong G.X.; Zhang J.D.; Chen Y.P.; Wang Q.; Zeng Q.P.; Alzheimer\u2018s disease-like early-phase brain pathogenesis: Self-curing amelioration of neurodegeneration from pro-inflammatory \u2019wounding\u2019 to anti-inflammatory \u2018healing\u2019. Curr Alzheimer Res 2017,17(10)","journal-title":"Curr Alzheimer Res"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2165\/11631830-000000000-00000","volume":"72","author":"Pouryamout L.","year":"2012","unstructured":"Pouryamout L.; Dams J.; Wasem J.; Dodel R.; Neumann A.; Economic evaluation of treatment options in patients with alzheimer\u2019s disease: A systematic review of cost-effectiveness analyses. Drugs 2012,72(6),789-802","journal-title":"Drugs"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","volume":"28","author":"Patel L.","year":"2011","unstructured":"Patel L.; Grossberg G.T.; Combination therapy for alzheimer\u2019s disease. Drugs Aging 2011,28(7),539-546","journal-title":"Drugs Aging"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2015.05.510","volume":"37","author":"Ehret M.J.","year":"2015","unstructured":"Ehret M.J.; Chamberlin K.W.; Current practices in the treatment of alzheimer disease: Where is the evidence after the phase iii trials? Clin Ther 2015,37(8),1604-1616","journal-title":"Clin Ther"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","volume":"32","author":"Deardorff W.J.","year":"2015","unstructured":"Deardorff W.J.; Feen E.; Grossberg G.T.; The use of cholinesterase inhibitors across all stages of alzheimer\u2019s disease. Drugs Aging 2015,32(7),537-547","journal-title":"Drugs Aging"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2174\/0929867323666160418114733","volume":"23","author":"Pohanka M.","year":"2016","unstructured":"Pohanka M.; Vaccination to alzheimer disease. Is it a promising tool or a blind way? Curr Med Chem 2016,23(14),1432-1441","journal-title":"Curr Med Chem"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jamda.2016.06.009","volume":"17","author":"Sterner R.M.","year":"2016","unstructured":"Sterner R.M.; Takahashi P.Y.; Yu Ballard A.C.; Active vaccines for alzheimer disease treatment. J Am Med Dir Assoc 2016,17(9),25","journal-title":"J Am Med Dir Assoc"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/nan.12050","volume":"40","author":"Hartig W.","year":"2014","unstructured":"Hartig W.; Saul A.; Kacza J.; Grosche J.; Goldhammer S.; Michalski D.; Wirths O.; Immunolesion-induced loss of cholinergic projection neurones promotes beta-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice. Neuropathol Appl Neurobiol 2014,40(2),106-120","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/187152711795563976","volume":"10","author":"Abdel-Salam O.M.","year":"2011","unstructured":"Abdel-Salam O.M.; Stem cell therapy for alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2011,10(4),459-485","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4103\/1673-5374.213541","volume":"12","author":"Hiremathad A.","year":"2017","unstructured":"Hiremathad A.; Piemontese L.; Heterocyclic compounds as key structures for the interaction with old and new targets in alzheimer\u2019s disease therapy. Neural Regen Res 2017,12(8),1256-1261","journal-title":"Neural Regen Res"},{"key":"ref=94","first-page":"31509","volume":"20","author":"Makhaeva G.F.","year":"2017","unstructured":"Makhaeva G.F.; Lushchekina S.V.; Boltneva N.P.; Serebryakova O.G.; Rudakova E.V.; Ustyugov A.A.; Bachurin S.O.; Shchepochkin A.V.; Chupakhin O.N.; Charushin V.N.; Richardson R.J.; 9-substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for alzheimer\u2019s disease treatment. Bioorg Med Chem 2017,20(17),31509-31502","journal-title":"Bioorg Med Chem"},{"key":"ref=95","first-page":"13111","volume":"25","author":"Skibinski R.","year":"2017","unstructured":"Skibinski R.; Czarnecka K.; Girek M.; Bilichowski I.; Chufarova N.; Mikiciuk-Olasik E.; Szymanski P.; Novel tetrahydroacridine derivatives with iodobenzoic acid moiety as multifunctional acetylcholinesterase inhibitors. Chem Biol Drug Des 2017,25(10),13111","journal-title":"Chem Biol Drug Des"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/1874104501711010024","volume":"11","author":"Teponnou G.A.K.","year":"2017","unstructured":"Teponnou G.A.K.; Joubert J.; Malan S.F.; Tacrine, trolox and tryptoline as lead compounds for the design and synthesis of multi-target agents for alzheimer\u2019s disease therapy. Open Med Chem J 2017,11,24-37","journal-title":"Open Med Chem J"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/molecules21040400","volume":"21","author":"Boulebd H.","year":"2016","unstructured":"Boulebd H.; Ismaili L.; Bartolini M.; Bouraiou A.; Andrisano V.; Martin H.; Bonet A.; Moraleda I.; Iriepa I.; Chioua M.; Belfaitah A.; Marco-Contelles J.; Imidazopyranotacrines as non-hepatotoxic, selective acetylcholinesterase inhibitors, and antioxidant agents for alzheimer\u2019s disease therapy. Molecules 2016,21(4),400","journal-title":"Molecules"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fnins.2016.00205","volume":"10","author":"Unzeta M.","year":"2016","unstructured":"Unzeta M.; Esteban G.; Bolea I.; Fogel W.A.; Ramsay R.R.; Youdim M.B.; Tipton K.F.; Marco-Contelles J.; Multi-target directed donepezil-like ligands for alzheimer\u2019s disease. Front Neurosci 2016,10,205","journal-title":"Front Neurosci"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","volume":"75","author":"Bautista-Aguilera O.M.","year":"2014","unstructured":"Bautista-Aguilera O.M.; Esteban G.; Bolea I.; Nikolic K.; Agbaba D.; Moraleda I.; Iriepa I.; Samadi A.; Soriano E.; Unzeta M.; Marco-Contelles J.; Design, synthesis, pharmacological evaluation, qsar analysis, molecular modeling and admet of novel donepezil-indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of alzheimer\u2019s disease. Eur J Med Chem 2014,75,82-95","journal-title":"Eur J Med Chem"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ejmech.2017.08.021","volume":"139","author":"Palanimuthu D.","year":"2017","unstructured":"Palanimuthu D.; Poon R.; Sahni S.; Anjum R.; Hibbs D.; Lin H.Y.; Bernhardt P.V.; Kalinowski D.S.; Richardson D.R.; A novel class of thiosemicarbazones show multi-functional activity for the treatment of alzheimer\u2019s disease. Eur J Med Chem 2017,139,612-632","journal-title":"Eur J Med Chem"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.bmc.2017.02.027","volume":"25","author":"Luo L.","year":"2017","unstructured":"Luo L.; Li Y.; Qiang X.; Cao Z.; Xu R.; Yang X.; Xiao G.; Song Q.; Tan Z.; Deng Y.; Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and beta-amyloid aggregation inhibitory activities as potential agents against alzheimer\u2019s disease. Bioorg Med Chem 2017,25(6),1997-2009","journal-title":"Bioorg Med Chem"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.bmc.2016.12.013","volume":"25","author":"Xiao G.","year":"2017","unstructured":"Xiao G.; Li Y.; Qiang X.; Xu R.; Zheng Y.; Cao Z.; Luo L.; Yang X.; Sang Z.; Su F.; Deng Y.; Design, synthesis and biological evaluation of 4\u2032-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of alzheimer\u2019s disease. Bioorg Med Chem 2017,25(3),1030-1041","journal-title":"Bioorg Med Chem"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/eesa.1998.1721","volume":"42","author":"Sturm A.","year":"1999","unstructured":"Sturm A.; Hansen P.; Altered cholinesterase and monooxygenase levels in daphnia magna and chironomus riparius exposed to environmental pollutants. Ecotoxicol Environ Saf 1999,42(1),9-15","journal-title":"Ecotoxicol Environ Saf"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00204-003-0452-0","volume":"77","author":"Mutch E.","year":"2003","unstructured":"Mutch E.; Daly A.K.; Leathart J.B.; Blain P.G.; Williams F.M.; Do multiple cytochrome p450 isoforms contribute to parathion metabolism in man? Arch Toxicol 2003,77(6),313-320","journal-title":"Arch Toxicol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/nyas.13156","volume":"1","author":"Jan Y.H.","year":"2016","unstructured":"Jan Y.H.; Richardson J.R.; Baker A.A.; Mishin V.; Heck D.E.; Laskin D.L.; Laskin J.D.; Novel approaches to mitigating parathion toxicity: Targeting cytochrome p450-mediated metabolism with menadione. Ann N Y Acad Sci 2016,1,80-86","journal-title":"Ann N Y Acad Sci"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2007.08.081","volume":"241","author":"Buratti F.M.","year":"2007","unstructured":"Buratti F.M.; Testai E.; Evidences for cyp3a4 autoactivation in the desulfuration of dimethoate by the human liver. Toxicology 2007,241(1-2),33-46","journal-title":"Toxicology"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.ento.44.1.507","volume":"44","author":"Feyereisen R.","year":"1999","unstructured":"Feyereisen R.; Insect p450 enzymes. Annu Rev Entomol 1999,44,507-533","journal-title":"Annu Rev Entomol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/15376516.2011.589089","volume":"21","author":"Pohanka M.","year":"2011","unstructured":"Pohanka M.; Novotny L.; Pikula J.; Metrifonate alters antioxidant levels and caspase activity in cerebral cortex of wistar rats. Toxicol Mech Method 2011,21(8),585-590","journal-title":"Toxicol Mech Method"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","volume":"19","author":"Nordberg A.","year":"1998","unstructured":"Nordberg A.; Svensson A.L.; Cholinesterase inhibitors in the treatment of alzheimer\u2019s disease - a comparison of tolerability and pharmacology. Drug Saf 1998,19(6),465-480","journal-title":"Drug Saf"},{"key":"ref=110","author":"L\u00f3pez-Arrieta J.M.","year":"2006","unstructured":"L\u00f3pez-Arrieta J.M.; Schneider L.; Metrifonate for alzheimer\u2019s disease. Cochrane Database Syst Rev 2006(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/089198870101400211","volume":"14","author":"Cummings J.L.","year":"2001","unstructured":"Cummings J.L.; Nadel A.; Masterman D.; Cyrus P.A.; Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with alzheimer\u2019s disease. J Geriatr Psychiatry Neurol 2001,14(2),101-108","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref=112","first-page":"564","volume":"105","author":"Mirck M.H.","year":"1980","unstructured":"Mirck M.H.; Use of trichlorfon as an anthelmintic in horses. Tijdschr Diergeneeskd 1980,105(14),564-566","journal-title":"Tijdschr Diergeneeskd"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vetpar.2009.07.045","volume":"166","author":"Lopes W.D.","year":"2009","unstructured":"Lopes W.D.; dos Santos T.R.; Borges Fde A.; Sakamoto C.A.; Soares V.E.; Costa G.H.; Camargo G.; Pulga M.E.; Bhushan C.; da Costa A.J.; Anthelmintic efficacy of oral trichlorfon solution against ivermectin resistant nematode strains in cattle. Vet Parasitol 2009,166(1-2),98-102","journal-title":"Vet Parasitol"},{"key":"ref=114","first-page":"011","volume":"109","author":"Fiel C.","year":"2011","unstructured":"Fiel C.; Guzman M.; Steffan P.; Rodriguez E.; Prieto O.; Bhushan C.; The efficacy of trichlorphon and naphthalophos against multiple anthelmintic-resistant nematodes of naturally infected sheep in argentina. Parasitol Res 2011,109(1),011-2410","journal-title":"Parasitol Res"},{"key":"ref=115","first-page":"71","volume":"8","author":"Lopez-Arias A.","year":"2015","unstructured":"Lopez-Arias A.; Villar-Argaiz D.; Chaparro-Gutierrez J.J.; Miller R.J.; Perez de Leon A.A.; Reduced efficacy of commercial acaricides against populations of resistant cattle tick rhipicephalus microplus from two municipalities of antioquia, colombia. Environ Health Insights 2015,8(Suppl. 2),71-80","journal-title":"Environ Health Insights"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.tiv.2015.01.001","volume":"29","author":"Fernandes L.S.","year":"2015","unstructured":"Fernandes L.S.; Emerick G.L.; dos Santos N.A.; de Paula E.S.; Barbosa F.; dos Santos A.C.; In vitro study of the neuropathic potential of the organophosphorus compounds trichlorfon and acephate. Toxicol In Vitro 2015,29(3),522-528","journal-title":"Toxicol In Vitro"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S0022149X1400039X","volume":"89","author":"Martin R.J.","year":"2015","unstructured":"Martin R.J.; Puttachary S.; Buxton S.K.; Verma S.; Robertson A.P.; The conqueror worm: Recent advances with cholinergic anthelmintics and techniques excite research for better therapeutic drugs. J Helminthol 2015,89(4),387-397","journal-title":"J Helminthol"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2885.2002.00423.x","volume":"25","author":"Zinser E.W.","year":"2002","unstructured":"Zinser E.W.; Wolf M.L.; Alexander-Bowman S.J.; Thomas E.M.; Davis J.P.; Groppi V.E.; Lee B.H.; Thompson D.P.; Geary T.G.; Anthelmintic paraherquamides are cholinergic antagonists in gastrointestinal nematodes and mammals. J Vet Pharmacol Ther 2002,25(4),241-250","journal-title":"J Vet Pharmacol Ther"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(96)00027-1","volume":"301","author":"Aas P.","year":"1996","unstructured":"Aas P.; In vitro effects of toxogonin, hi-6 and hl\u00f6-7 on the release of [3h]acetylcholine from peripheral cholinergic nerves in rat airway smooth muscle. Eur J Pharmacol 1996,301(1-3),59-66","journal-title":"Eur J Pharmacol"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/0272-0590(84)90143-X","volume":"4","author":"Cetkovic S.","year":"1984","unstructured":"Cetkovic S.; Cvetkovic M.; Jandric D.; Cosic M.; Boskovic B.; Effect of pam-2 cl, hi-6, and hgg-12 in poisoning by tabun and its thiocholine-like analog in the rat. Fundam Appl Toxicol 1984,4(2),S116-S123","journal-title":"Fundam Appl Toxicol"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/bdd.2510160804","volume":"16","author":"Nyberg A.G.","year":"1995","unstructured":"Nyberg A.G.; Cassel G.; Jeneskog T.; Karlsson L.; Larsson R.; Lundstrom M.; Palmer L.; Persson S.A.; Pharmacokinetics of hi-6 and atropine in anesthetized pigs after administration by a new autoinjector. Biopharm Drug Dispos 1995,16(8),635-651","journal-title":"Biopharm Drug Dispos"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/jat.788","volume":"21","author":"Crenshaw M.D.","year":"2001","unstructured":"Crenshaw M.D.; Hayes T.L.; Miller T.L.; Shannon C.M.; Comparison of the hydrolytic stability of s-(n,n-diethylaminoethyl) isobutyl methylphosphonothiolate with vx in dilute solution. J Appl Toxicol 2001,21,S3-S6","journal-title":"J Appl Toxicol"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/0006-2952(93)90106-7","volume":"46","author":"Dejong L.P.A.","year":"1993","unstructured":"Dejong L.P.A.; Vandijk C.; Berhitoe D.; Benschop H.P.; Hydrolysis and binding of a toxic stereoisomer of soman in plasma and tissue-homogentaes from rat, guinea-pig and marmoset, and in human plasma. Biochem Pharmacol 1993,46(8),1413-1419","journal-title":"Biochem Pharmacol"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0300-483X(99)00029-3","volume":"134","author":"Tuovinen K.","year":"1999","unstructured":"Tuovinen K.; Kaliste-Korhonen E.; Raushel F.M.; Hanninen O.; Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology 1999,134(2-3),169-178","journal-title":"Toxicology"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.etap.2011.10.002","volume":"33","author":"Cho Y.","year":"2012","unstructured":"Cho Y.; Kim W.S.; Hur G.H.; Ha Y.C.; Minimum effective drug concentrations of a transdermal patch system containing procyclidine and physostigmine for prophylaxis against soman poisoning in rhesus monkeys. Environ Toxicol Pharmacol 2012,33(1),1-8","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbr.2008.08.031","volume":"197","author":"Lamproglou I.","year":"2009","unstructured":"Lamproglou I.; Barbier L.; Diserbo M.; Fauvelle F.; Fauquette W.; Amourette C.; Repeated stress in combination with pyridostigmine part i: Long-term behavioural consequences. Behav Brain Res 2009,197(2),301-310","journal-title":"Behav Brain Res"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cbi.2005.10.031","volume":"157","author":"Gordon R.K.","year":"2005","unstructured":"Gordon R.K.; Haigh J.R.; Garcia G.E.; Feaster S.R.; Riel M.A.; Lenz D.E.; Aisen P.S.; Doctor B.P.; Oral administration of pyridostigmine bromide and huperzine a protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact 2005,157,239-246","journal-title":"Chem Biol Interact"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1073\/pnas.0711986105","volume":"105","author":"Golomb B.A.","year":"2008","unstructured":"Golomb B.A.; Acetylcholinesterase inhibitors and gulf war illnesses. Proc Natl Acad Sci U S A 2008,105(11),4295-4300","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref=129","first-page":"332","volume":"39","author":"Auxemery Y.","year":"2013","unstructured":"Auxemery Y.; The gulf war syndrome twenty years on. Enceph.-. Rev Psychiatr Clin Biol Ther 2013,39(5),332-338","journal-title":"Rev Psychiatr Clin Biol Ther"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jat.1210","volume":"27","author":"Dubovicky M.","year":"2007","unstructured":"Dubovicky M.; Paton S.; Morris M.; Mach M.; Lucot J.B.; Effects of combined exposure to pyridostigmine bromide and shaker stress on acoustic startle response, pre-pulse inhibition and open field behavior in mice. J Appl Toxicol 2007,27(3),276-283","journal-title":"J Appl Toxicol"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","volume":"49","author":"Romi F.","year":"2017","unstructured":"Romi F.; Hong Y.; Gilhus N.E.; Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol 2017,49,9-13","journal-title":"Curr Opin Immunol"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"Hehir M.K.","year":"2017","unstructured":"Hehir M.K.; Hobson-Webb L.D.; Benatar M.; Barnett C.; Silvestri N.J.; Howard J.F.; Howard D.; Visser A.; Crum B.A.; Nowak R.; Beekman R.; Kumar A.; Ruzhansky K.; Chen I.A.; Pulley M.T.; LaBoy S.M.; Fellman M.A.; Greene S.M.; Pasnoor M.; Burns T.M.; Rituximab as treatment for anti-musk myasthenia gravis: Multicenter blinded prospective review. Neurology 2017,89(10),1069-1077","journal-title":"Neurology"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.nmd.2017.06.012","volume":"27","author":"Muto K.","year":"2017","unstructured":"Muto K.; Matsui N.; Unai Y.; Sakai W.; Haji S.; Udaka K.; Miki H.; Furukawa T.; Abe M.; Kaji R.; Memory b cell resurgence requires repeated rituximab in myasthenia gravis. Neuromuscul Disord 2017,27(10),918-922","journal-title":"Neuromuscul Disord"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40266-015-0297-2","volume":"32","author":"Alkhawajah N.M.","year":"2015","unstructured":"Alkhawajah N.M.; Oger J.; Treatment of myasthenia gravis in the aged. Drugs Aging 2015,32(9),689-697","journal-title":"Drugs Aging"},{"key":"ref=135","first-page":"14","volume":"6956298","author":"Khan M.S.","year":"2017","unstructured":"Khan M.S.; Tiwari A.; Khan Z.; Sharma H.; Taleb M.; Hammersley J.; Pyridostigmine induced prolonged asystole in a patient with myasthenia gravis successfully treated with hyoscyamine. Case Rep Cardiol 2017,6956298(10),14","journal-title":"Case Rep Cardiol"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2016.01.006","volume":"292","author":"Patil S.A.","year":"2016","unstructured":"Patil S.A.; Bokoliya S.C.; Nagappa M.; Taly A.B.; Diagnosis of myasthenia gravis: Comparison of anti-nicotinic acetyl choline receptor antibodies, repetitive nerve stimulation and neostigmine tests at a tertiary neuro care centre in india, a ten year study. J Neuroimmunol 2016,292,81-84","journal-title":"J Neuroimmunol"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CND.0000000000000162","volume":"19","author":"Nazari F.","year":"2017","unstructured":"Nazari F.; Abdi S.; Pyridostigmine-induced bradycardia in patient with musk-ab-positive myasthenia gravis and alopecia universalis. J Clin Neuromuscul Dis 2017,19(1),49-50","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref=138","volume":"27","author":"Petrov K.","year":"2015","unstructured":"Petrov K.; Macrocyclic derivatives of 6-methyluracil: New ligands of the peripheral anionic site of acetylcholinesterase. Int J Risk Saf Med 2015,27(1)","journal-title":"Int J Risk Saf Med"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1042\/BCJ20160084","volume":"473","author":"Kharlamova A.D.","year":"2016","unstructured":"Kharlamova A.D.; Lushchekina S.V.; Petrov K.A.; Kots E.D.; Nachon F.; Villard-Wandhammer M.; Zueva I.V.; Krejci E.; Reznik V.S.; Zobov V.V.; Nikolsky E.E.; Masson P.; Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: Mechanism and possible advantages for myasthenia gravis treatment. Biochem J 2016,473(9),1225-1236","journal-title":"Biochem J"},{"key":"ref=140","first-page":"949","volume":"14","author":"Feng X.","year":"2015","unstructured":"Feng X.; Wang X.; Liu Y.; Di X.; Linarin inhibits the acetylcholinesterase activity in-vitro and ex-vivo. Iran J Pharm Res 2015,14(3),949-954","journal-title":"Iran J Pharm Res"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nri2566","volume":"9","author":"Tracey K.J.","year":"2009","unstructured":"Tracey K.J.; Reflex control of immunity. Nat Rev Immunol 2009,9(6),418-428","journal-title":"Nat Rev Immunol"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2796.2009.02098.x","volume":"265","author":"Rosas-Ballina M.","year":"2009","unstructured":"Rosas-Ballina M.; Tracey K.J.; Cholinergic control of inflammation. J Intern Med 2009,265(6),663-679","journal-title":"J Intern Med"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10517-012-1803-8","volume":"153","author":"Zabrodskii P.F.","year":"2012","unstructured":"Zabrodskii P.F.; Lim V.G.; Shekhter M.S.; Kuzmin A.V.; Role of nicotinic and muscarinic cholinoreceptors in the realization of the cholinergic anti-inflammatory pathway during the early phase of sepsis. Bull Exp Biol Med 2012,153(5),700-703","journal-title":"Bull Exp Biol Med"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.resp.2013.02.002","volume":"187","author":"Tonhajzerova I.","year":"2013","unstructured":"Tonhajzerova I.; Mokra D.; Visnovcova Z.; Vagal function indexed by respiratory sinus arrhythmia and cholinergic anti-inflammatory pathway. Respir Physiol Neurobiol 2013,187(1),78-81","journal-title":"Respir Physiol Neurobiol"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000342714","volume":"12","author":"Noelker C.","year":"2013","unstructured":"Noelker C.; Stuckenholz V.; Reese J.P.; Alvarez-Fischer D.; Sankowski R.; Rausch T.; Oertel W.H.; Hartmann A.; van Patten S.; Al-Abed Y.; Bacher M.; Cni-1493 attenuates neuroinflammation and dopaminergic neurodegeneration in the acute mptp mouse model of parkinson\u2019s disease. Neurodegener Dis 2013,12(2),103-110","journal-title":"Neurodegener Dis"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.2174\/138161212800165951","volume":"18","author":"Forsythe P.","year":"2012","unstructured":"Forsythe P.; The nervous system as a critical regulator of immune responses underlying allergy. Curr Pharm Des 2012,18(16),2290-2304","journal-title":"Curr Pharm Des"},{"key":"ref=147","first-page":"30451","volume":"9","author":"Song F.","year":"2017","unstructured":"Song F.; Zhao L.; Zhu R.; Song Q.; Deng J.; Tian R.; Wang F.; Qian Y.; Protective effect of an alpha 7 nicotinic acetylcholine receptor agonist against enterovirus 71 infection in neuronal cells. Antiviral Res 2017,9(17),30451-30455","journal-title":"Antiviral Res"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.3390\/ijms15069809","volume":"15","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; Inhibitors of acetylcholinesterase and butyrylcho-linesterase meet immunity. Int J Mol Sci 2014,15(6),9809-9825","journal-title":"Int J Mol Sci"},{"key":"ref=149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jab.2014.09.001.","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; Caffeine downregulates antibody production in a mouse model. J Appl Biomed In press2014","journal-title":"J Appl Biomed"},{"key":"ref=150","first-page":"155","volume":"35","author":"Pohanka M.","year":"2014","unstructured":"Pohanka M.; Effect of hi-6 on cytokines production after immunity stimulation by keyhole limpet hemocyanin in a mouse model. Neuroendocrinol Lett 2014,35,155-157","journal-title":"Neuroendocrinol Lett"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.etap.2013.07.012","volume":"36","author":"Pohanka M.","year":"2013","unstructured":"Pohanka M.; Hi-6 modulates immunization efficacy in a balb\/c mouse model. Environ Toxicol Pharmacol 2013,36(3),801-806","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1471-4159.2008.05504.x","volume":"106","author":"Wang Z.F.","year":"2008","unstructured":"Wang Z.F.; Wang J.; Zhang H.Y.; Tang X.C.; Huperzine a exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem 2008,106(4),1594-1603","journal-title":"J Neurochem"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.febslet.2007.01.016","volume":"581","author":"Wang Z.F.","year":"2007","unstructured":"Wang Z.F.; Tang X.C.; Huperzine a protects c6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett 2007,581(4),596-602","journal-title":"FEBS Lett"},{"key":"ref=154","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/a4f6882e-e174-4bfb-bbcc-8d380d5dd225","volume":"8","author":"Kalb A.","year":"2013","unstructured":"Kalb A.; von Haefen C.; Sifringer M.; Tegethoff A.; Paeschke N.; Kostova M.; Feldheiser A.; Spies C.D.; Acetylcholinesterase inhibitors reduce neuroinflammation and -degeneration in the cortex and hippocampus of a surgery stress rat model. PLoS One 2013,8(5)","journal-title":"PLoS One"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/175866","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/175866\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/175866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T19:38:35Z","timestamp":1615577915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/175866\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":154,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,10,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666191018170908","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}